Hims & Hers Health, Inc.
Has Hims & Hers Health, Inc. received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued Hims & Hers Health, Inc. 2 warning letters naming semaglutide, the latest dated Sep 9, 2025, with the FDA subject line “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth).”
FDA records in this index name Hims & Hers Health, Inc. on Sep 9, 2025.
- Names in FDA records
- Hims & Hers Health, Inc. dba Hers; Hims & Hers Health, Inc. dba Hims
- Websites the letters name
- forhers.com, hims.com (see how each letter refers to them)
- Type named in FDA records
- Telehealth
- FDA warning letters
- 2
- Drug recall reports
- 0
- Drugs named
- Semaglutide
- Latest record
- Sep 9, 2025
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Sep 9, 2025: … website offers various compounded drug products, including semaglutide . As described below, your claims concerning compounded semaglutide products are false or misleading under sections … The following claims concerning your compounded semaglutide products appear on your website: • “Weekly … Full letter
- Sep 9, 2025: … website offers various compounded drug products, including semaglutide . As described below, your claims concerning your compounded semaglutide products are false or misleading under sections … The following claims concerning your compounded semaglutide products appear on your website: • “Same active … Full letter
Websites named in the letters
Each letter below is addressed to the firm FDA names in it, not to a website. The sentence quoted is the letter’s own reference to the site, copied from the letter on fda.gov.
- forhers.com: FDA’s warning letter of Sep 9, 2025 is addressed to Hims & Hers Health, Inc. dba Hers. It refers to the site in these words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.forhers.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” Full letter
- hims.com: FDA’s warning letter of Sep 9, 2025 is addressed to Hims & Hers Health, Inc. dba Hims. It refers to the site in these words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.hims.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” Full letter
Drug recalls
No openFDA drug recall reports in this index.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letter, Sep 9, 2025
- FDA warning letter, Sep 9, 2025
- FDA warning letters (fda.gov full-text search)
Records last pulled Nov 15, 2026. Every entry links to the original public record.